Citius Pharmaceuticals, Inc. CTXRW 深 滬
已收盤 08-08 16:00:00 美东时间
0.1441
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.1441
- 總市值 1941.04万
- 52周最高 1.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.012
- 委 比 0.00%
- 總股本 1.35亿
- 歷史最高 2.89
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.012
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Citius Oncology Announces Pricing of $9.0 Million Public Offering
CRANFORD, N.J., July 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: ...
07-16 21:15
Cencora distribution deal boosts Citius shares
Citius Pharmaceuticals (NASDAQ:CTXR) traded higher in the premarket on Tuesday after the company announced that its majority-owned subsidiary, Citius Oncology (NASDAQ:CTOR), reached a distribution ser...
07-15 20:56
Citius Oncology Partners With Cencora To Boost Commercial Launch And Distribution Of FDA-Approved Immunotherapy LYMPHIR
Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for FDA-approved immunotherapy LYMPHIR™CRANFORD, N.J., July 15, 2025 /PRNewswire/ --
07-15 20:35
Citius Pharmaceuticals regains Nasdaq compliance
Citius Pharmaceuticals (NASDAQ:CTXR) announced on Tuesday it received a Nasdaq notification, indicating that the company regained compliance with Nasdaq's minimum bid price requirement rule of $1.00 p...
07-08 20:48
Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
CRANFORD, N.J. , July 8, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) today announced that it has received formal notification from Th...
07-08 20:34
D. Boral Capital Maintains Buy on Citius Pharmaceuticals, Maintains $6 Price Target
D. Boral Capital analyst Jason Kolbert maintains Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy and maintains $6 price target.
06-30 19:24
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025
CRANFORD, N.J., June 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nas...
06-17 20:08
Citius Pharmaceuticals Closes $6M Securities Offering
An update from Citius Pharmaceuticals ( ($CTXR) ) is now available. On June 9, ...
06-12 21:17
Citius Pharmaceuticals slides on $15.8M securities offering
Citius Pharmaceuticals (NASDAQ:CTXR) announced on Tuesday that it has entered into definitive agreements for the purchase of an aggregate of 4.92 million shares of its common stock and accompanying sh...
06-10 19:40
Citius Pharma Secures $1.22/Share Direct Offering, Selling 4.92M Shares & Warrants
$6 million upfront with up to an additional $9.8 million of potential aggregate gross proceeds upon the exercise in full of short-term warrantsCRANFORD, N.J., June 10, 2025 /PRNewswire/ -- Citius Pharmaceuticals
06-10 19:18
